nilotinib

Generic: nilotinib

Labeler: camber pharmaceuticals, inc.
NDC Directory HUMAN PRESCRIPTION DRUG ANDA Inactive Finished

Drug Facts

Product Profile

Brand Name nilotinib
Generic Name nilotinib
Labeler camber pharmaceuticals, inc.
Dosage Form CAPSULE
Routes
ORAL
Active Ingredients

nilotinib 150 mg/1

Manufacturer
Camber Pharmaceuticals, Inc.

Identifiers & Regulatory

Product NDC 31722-779
Product ID 31722-779_44065ee4-1b6c-f3ef-e063-6394a90a797a
Product Type HUMAN PRESCRIPTION DRUG
Marketing Category ANDA
Application Number ANDA209651
Listing Expiration 2026-12-31
Marketing Start 2025-11-19

Pharmacologic Class

Established (EPC)
kinase inhibitor [epc]
Mechanism of Action
bcr-abl tyrosine kinase inhibitors [moa] cytochrome p450 2c8 inhibitors [moa] cytochrome p450 2d6 inhibitors [moa] cytochrome p450 2b6 inducers [moa] cytochrome p450 2c8 inducers [moa] ugt1a1 inhibitors [moa] p-glycoprotein inhibitors [moa]

Normalized Code Variants

Searchable formats for this product NDC code

Digits Only 31722779
Hyphenated Format 31722-779

Supplemental Identifiers

RxCUI
746606 997653
UNII
F41401512X
NUI
N0000175605 N0000020009 N0000187062 N0000182137 N0000187064 N0000187063 N0000191272 N0000185503

Packaging Origin

Original Packager
true

Resolved Product View

Precedence rule: structured NDC data is preferred, falling back to linked label metadata when unavailable. Source tags show the origin of each value.

Resolved Identity

Brand Name nilotinib (source: ndc)
Generic Name nilotinib (source: ndc)
Application Number ANDA209651 (source: ndc)
Routes
ORAL
source: ndc

Resolved Composition

Strengths
  • 150 mg/1
source: ndc
Packaging
  • 4 BLISTER PACK in 1 CARTON (31722-779-33) / 28 CAPSULE in 1 BLISTER PACK
source: ndc

Packages (1)

31722-779-33 4 BLISTER PACK in 1 CARTON (31722-779-33) / 28 CAPSULE in 1 BLISTER PACK

Ingredients (1)

nilotinib (150 mg/1)

Linked Drug Pages (1)

Nilotinib ndc-match (0.9)

Raw FDA Data

View complete raw FDA NDC JSON payload 
{"route": ["ORAL"], "spl_id": "44065ee4-1b6c-f3ef-e063-6394a90a797a", "openfda": {"nui": ["N0000175605", "N0000020009", "N0000187062", "N0000182137", "N0000187064", "N0000187063", "N0000191272", "N0000185503"], "unii": ["F41401512X"], "rxcui": ["746606", "997653"], "spl_set_id": ["86dc5507-ae0a-43d2-8d5e-5b0568ce9c5e"], "pharm_class_epc": ["Kinase Inhibitor [EPC]"], "pharm_class_moa": ["Bcr-Abl Tyrosine Kinase Inhibitors [MoA]", "Cytochrome P450 2C8 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C8 Inducers [MoA]", "UGT1A1 Inhibitors [MoA]", "P-Glycoprotein Inhibitors [MoA]"], "manufacturer_name": ["Camber Pharmaceuticals, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "4 BLISTER PACK in 1 CARTON (31722-779-33)  / 28 CAPSULE in 1 BLISTER PACK", "package_ndc": "31722-779-33", "marketing_start_date": "20251119"}], "brand_name": "Nilotinib", "product_id": "31722-779_44065ee4-1b6c-f3ef-e063-6394a90a797a", "dosage_form": "CAPSULE", "pharm_class": ["Bcr-Abl Tyrosine Kinase Inhibitors [MoA]", "Cytochrome P450 2B6 Inducers [MoA]", "Cytochrome P450 2C8 Inducers [MoA]", "Cytochrome P450 2C8 Inhibitors [MoA]", "Cytochrome P450 2D6 Inhibitors [MoA]", "Kinase Inhibitor [EPC]", "P-Glycoprotein Inhibitors [MoA]", "UGT1A1 Inhibitors [MoA]"], "product_ndc": "31722-779", "generic_name": "Nilotinib", "labeler_name": "Camber Pharmaceuticals, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Nilotinib", "active_ingredients": [{"name": "NILOTINIB", "strength": "150 mg/1"}], "application_number": "ANDA209651", "marketing_category": "ANDA", "marketing_start_date": "20251119", "listing_expiration_date": "20261231"}